GlobeNewswire Inc.··Amphista TherapeuticsAmphista Therapeutics Names New Leadership to Advance AMX-883 Toward IND Filing
Amphista Therapeutics appoints new CEO and CMO ahead of planned AMX-883 IND application in April 2026 for acute myeloid leukemia treatment.
LLYNVSclinical developmentIND application